My ePortfolio Register   

TAT 2017 congress provides the latest in Phase I targeted therapies

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.11.16
Views: 829

Professor Jean-Charles Soria - Gustave Roussy, Paris, France

Prof Soria talks to ecancertv about the upcoming 15th International Congress on Targeted Anticancer Therapies (TAT 2017).

The role of Phase I studies in oncology drug development is changing, he says, explaining that Phase I is no longer just about checking for toxicity, but also enriching patients with better predictive markers of efficacy and ascertaining objective responses.

He tells us how TAT brings a blend of academics and industry partners together from all over the world, specialising in targeted therapies and immunotherapies.

Because of its size and because there are no parallel sessions, the programme is easy to follow and allows for friendly interactions between key opinion leaders, young investigators and industry, he says.

For more on the TAT congress, we also have an interview with Dr Lesley Seymour.


Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence